Cite
Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRAS G12C -Mutant Lung Cancer.
MLA
Chour, Ali, et al. “Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRAS G12C -Mutant Lung Cancer.” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, vol. 18, no. 10, Oct. 2023, pp. 1408–15. EBSCOhost, https://doi.org/10.1016/j.jtho.2023.05.013.
APA
Chour, A., Denis, J., Mascaux, C., Zysman, M., Bigay-Game, L., Swalduz, A., Gounant, V., Cortot, A., Darrason, M., Fallet, V., Auclin, E., Basse, C., Tissot, C., Decroisette, C., Bombaron, P., Giroux-Leprieur, E., Odier, L., Brosseau, S., Creusot, Q., … Duruisseaux, M. (2023). Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRAS G12C -Mutant Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 18(10), 1408–1415. https://doi.org/10.1016/j.jtho.2023.05.013
Chicago
Chour, Ali, Julie Denis, Céline Mascaux, Maeva Zysman, Laurence Bigay-Game, Aurélie Swalduz, Valérie Gounant, et al. 2023. “Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRAS G12C -Mutant Lung Cancer.” Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 18 (10): 1408–15. doi:10.1016/j.jtho.2023.05.013.